Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors

Journal of Clinical Investigation

Volumn 113, Issue 11, 2004, Pages 1571-1581

  Sloop, Kyle W ^a   Cao, Julia Xiao Chun ^a   Siesky, Angela M ^a   Zhang, Hong Yan ^a   Bodenmiller, Diane M ^a   Cox, Amy L ^a   Jacobs, Steven J ^a   Moyers, Julie S ^a   Owens, Rebecca A ^a   Showalter, Aaron D ^a   Brenner, Martin B ^a   Raap, Achim ^a   Gromada, Jesper ^a   Berridge, Brian R ^a   Monteith, David K B ^a   Porksen, Niels ^a   McKay, Robert A ^b   Monia, Brett P ^b   Bhanot, Sanjay ^b   Watts, Lynnetta M ^b   Michael, M Dodson ^a   more..

^a ELI LILLY AND COMPANY   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' METHOXYETHYL MODIFIED PHOSPHOROTHIOATE ANTISENSE OLIGONUCLEOTIDE INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; CYCLIC AMP; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; GLUCOSE; INSULIN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; UNCLASSIFIED DRUG; ANTISENSE OLIGODEOXYNUCLEOTIDE; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; CYCLIC AMP REGULATED GENE; DIABETES MELLITUS; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; GENE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HYPERGLUCAGONEMIA; HYPERGLYCEMIA; INSULIN RELEASE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RODENT; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; LIVER; METABOLISM; RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; GLUCAGON-LIKE PEPTIDE 1; LIVER; MICE; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PEPTIDES; RATS; RECEPTORS, GLUCAGON;

EID: 85047693695     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI20911     Document Type: Article

References (35)

1. Unger, R.H. 1975. Letter: Glucagon in pathogenesis of diabetes. Lancet. 1:1036-1042.
2. Reaven, G.M., Chen, Y.D., Golay, A., Swislocki, A.L., and Jaspan, J.B. 1987. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 64:106-110.
3. Shah, P., et al. 2000. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 85:4053-4059.
4. Johnson, D.G., Goebel, C.U., Hruby, V.J., Bregman, M.D., and Trivedi, D. 1982. Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science. 215:1115-1116.
5. Unson, C.G., Gurzenda, E.M., and Merrifield, R.B. 1989. Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist. Peptides. 10:1171-1177.
6. Van Tine, B.A., et al. 1996. Low level cyclic adenosine 3′, 5′-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists. Endocrinology. 137:3316-3322.
7. Brand, C.L., et al. 1994. Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia. 37:985-993.
8. Brand, C.L., Jorgensen, P.N., Svendsen, I., and Hoist, J.J. 1996. Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes. 45:1076-1083.
9. Brand, C.L., Hansen, B., Groneman, S., Boysen, M., and Holst, J.J. 2000. Sub-chronic glucagon neutralisation improves diabetes in ob/ob mice [abstract]. Diabetes. 49:A81.
10. Petersen, K.F., and Sullivan, J.T. 2001. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia. 44:2018-2024.
11. Parker, J.C., Andrews, K.M., Allen, M.R., Stock, J.L., and McNeish, J.D. 2002. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem. Biophys. Res. Commun. 290:839-843.
12. Gelling, R.W., et al. 2003. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 100:1438-1443.
13. Webb, G.C., Akbar, M.S., Zhao, C., Swift, H.H., and Steiner, D.F. 2002. Glucagon replacement via micro-osmotic pump corrects hypoglycemia and α-cell hyperplasia in prohormone convertase 2 knockout mice. Diabetes. 51:398-405.
14. Zhang, H., et al. 2000. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat. Biotechnol. 18:862-867.
15. Yu, R.Z., et al. 2001. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J. Pharmacol. Exp. Ther. 296:388-395.
16. Liang, Y., et al. 2004. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes. 53:410-417.
17. Etgen, G.J., and Oldham, B.A. 2000. Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. Metabolism. 49:684-688.
18. Kieffer, T.J., Heller, R.S., Unson, C.G., Weir, G.G., and Habener, J.F. 1996. Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets. Endocrinology. 137:5119-5125.
19. Vincent, M., et al. 2003. Abrogation of protein convertase 2 activity results in delayed islet cell differentiation and maturarion, increased α-cell proliferation, and islet neogenesis. Endocrinology. 144:4061-4069.
20. Drucker, D.J. 2003. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol. Endocrinol. 17:161-171.
21. Holz, G.G., and Chepurny, O.G. 2003. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr. Med. Chem. 10:2471-2484.
22. Tinsley, F.C., Taicher, G.Z., and Heiman, M.L. 2004. Evaluation of a quantitative magnetic resonance method for mouse whole body composition analysis. Obes. Res. 12:150-160.
23. McCormack, J.G., Westergaard, N., Kristiansen, M., Brand, C.L., and Lau, J. 2001. Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy. Curr. Pharm. Des. 7:1451-1474.
24. Chastain, M.A. 2001. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J. Med. Sci. 321:306-320.
25. Hansen, L.H., et al. 1999. Identification of a glucagon receptor gene deletion mutation in a patient with hyperglucagonemia and pseudo-adenomatous hyperplasia of pancreatic α cells [abstract P3-441]. Programs and Abstracts: 81st Annual Meeting of the Endocrine Society. 441:533.
26. Butler, A.E., et al. 2003. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes. 52:102-110.
27. Drucker, D.J. 2001. Minireview: the glucagon-like peptides. Endocrinology. 142:521-527.
28. Uttenthal, L.O., et al. 1985. Molecular forms of glucagon-like peptide-1 in human pancreas and glucagonomas. J Clin. Endocrinol. Metab. 61:472-479.
29. Mojsov, S., Kopczynski, M.G., and Habener, J.F. 1990. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J. Biol. Chem. 265:8001-8008.
30. Nie, Y., et al. 2000. Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats. J. Clin. Invest. 105:955-965.
31. Ritzel, R., et al. 2001. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. Diabetes. 50:776-784.
32. Yasuda, N., Nagakura, T., Yamazaki, K., Inoue, T., and Tanaka, I. 2002. Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats. Life Sci. 71:227-238.
33. Cejvan, K., Coy, D.H., and Efendic, S. 2003. Intraislet somatostatin regulates glucagon release via type 2 somatostatin receptors in rats. Diabetes. 52:1176-1181.
34. McKay, R.A., et al. 1999. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-α expression. J. Biol Chem. 274:1715-1722.
35. Crooke, R.M., Graham, M.J., Cooke, M.E., and Crooke, S.T. 1995. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J. Pharmacol. Exp. Ther. 275:462-473.